Potent broadly reactive neutralising HIV-1 monoclonal antibodies

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/502617

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

A successful vaccine prevents infection. For HIV infection all candidate vaccines thus far have failed. From the many HIV-1 infected individuals there are a very small percentage that do not progress to disease. For these infected subjects we hypothesise that their immune responses are much better preserved and hence they will have stronger antibody responses. We have geared up our laboratory to characterise these strong antibodies and use them in making a better HIV-1 vaccine.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $463,168.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

HIV vaccines | HIV-AIDS | Immune development | envelope glycoprotein | human immunodeficiency virus infection | immune responses | neutralising antibodies | pathogenesis | vaccine development

Related Links